Should I buy or sell Curis stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRIS shares. View CRIS analyst ratings or view top-rated stocks .

What is Curis' stock price target for 2024?

3 Wall Street research analysts have issued 1-year price objectives for Curis' shares. Their CRIS share price targets range from $26.00 to $60.00. On average, they predict the company's share price to reach $37.33 in the next year. This suggests a possible upside of 156.4% from the stock's current price. View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts .

How have CRIS shares performed in 2024?

Curis' stock was trading at $12.75 on January 1st, 2024. Since then, CRIS stock has increased by 14.2% and is now trading at $14.56. View the best growth stocks for 2024 here .

When is Curis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRIS earnings forecast .

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) announced its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.91) by $0.12. The biotechnology company earned $2.70 million during the quarter, compared to the consensus estimate of $2.95 million. Curis had a negative net margin of 473.04% and a negative trailing twelve-month return on equity of 169.22%. During the same quarter last year, the business earned ($2.40) earnings per share.

When did Curis' stock split?

Curis's stock reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD) , Celldex Therapeutics (CLDX) , Micron Technology (MU) , Novavax (NVAX) , CTI BioPharma (CTIC) , Nabriva Therapeutics (NBRV) , Amarin (AMRN) , Idera Pharmaceuticals (IDRA) , ImmunoGen (IMGN) and OPKO Health (OPK) .

Who are Curis' major shareholders?

Curis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Street Advisors Inc. NC (0.34%). View institutional ownership trends .

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CRIS

Curis (CRIS) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free CRIS Stock Alerts

$14.56

-0.72 (-4.71%)

(As of 04/15/2024 ET)

Compare

Today's Range: $13.99
▼
$15.30
50-Day Range: $8.49
▼
$16.80
52-Week Range: $3.80
▼
$20.00

Volume: 20,188 shs
Average Volume: 37,897 shs
Market Capitalization: $85.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.33

Get Curis alerts:

Curis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 156.4% Upside
$37.33 Price Target
Short Interest: Healthy
0.85% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.92) to ($4.88) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.54 out of 5 stars

Medical Sector

664th out of 928 stocks

Biological Products, Except Diagnostic Industry

116th out of 156 stocks

3.5

Analyst's Opinion

Consensus Rating
Curis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Curis has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.85% of the float of Curis has been sold short.
Short Interest Ratio / Days to Cover
Curis has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Curis has recently increased by 4.59%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Curis does not currently pay a dividend.
Dividend Growth
Curis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRIS.

2.0

News and Social Media Coverage

News Sentiment
Curis has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Curis this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
3 people have added Curis to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Curis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.81% of the stock of Curis is held by insiders.
Percentage Held by Institutions
Only 29.97% of the stock of Curis is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Curis are expected to grow in the coming year, from ($5.92) to ($4.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Curis is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Curis is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Curis has a P/B Ratio of 4.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Curis Stock (NASDAQ:CRIS)

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CRIS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CRIS Stock News Headlines

April 9, 2024 | americanbankingnews.com

Curis (NASDAQ:CRIS) Stock Crosses Above 200-Day Moving Average of $10.49

April 5, 2024 | prnewswire.com

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

April 4, 2024 | prnewswire.com

Curis to Present at Upcoming Healthcare Conferences in April

April 2, 2024 | prnewswire.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)

March 28, 2024 | finance.yahoo.com

Curis, Inc. (CRIS) Stock Historical Prices & Data - Yahoo Finance

February 24, 2024 | benzinga.com

Curis Stock (NASDAQ:CRIS) Dividends: History, Yield and Dates

February 22, 2024 | benzinga.com

Curis Stock (NASDAQ:CRIS), Analyst Ratings, Price Targets, Predictions

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

February 10, 2024 | msn.com

Curis Inc. Is Worried About This – Should You Be Worried Too?

February 9, 2024 | finance.yahoo.com

Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript

February 8, 2024 | finanznachrichten.de

Curis, Inc.: Curis Provides Fourth Quarter 2023 Business Update

February 8, 2024 | markets.businessinsider.com

Curis Inc Q4 sales decline

February 8, 2024 | finance.yahoo.com

Curis Provides Fourth Quarter 2023 Business Update

February 7, 2024 | benzinga.com

Curis's Earnings: A Preview

February 1, 2024 | finance.yahoo.com

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

January 22, 2024 | finance.yahoo.com

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 18, 2023 | finance.yahoo.com

Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement

December 12, 2023 | markets.businessinsider.com

Buy Rating on Curis Backed by Promising Clinical Trials and Strategic Expansion

December 12, 2023 | finance.yahoo.com

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

December 11, 2023 | finance.yahoo.com

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

December 6, 2023 | markets.businessinsider.com

Positive Buy Rating for Curis Stock Driven by Emavusertib’s Clinical Promise and Revenue Potential

December 6, 2023 | finance.yahoo.com

Curis Announces Three Presentations at ASH

December 5, 2023 | markets.businessinsider.com

Curis Inks Deal With Florida University For Emavusertib/Pembrolizumab Combination Study In Melanoma

December 5, 2023 | finance.yahoo.com

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

November 18, 2023 | morningstar.com

Curis Inc CRIS

November 18, 2023 | msn.com

Truist Securities Initiates Coverage of Curis (CRIS) with Buy Recommendation

See More Headlines

Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:CRIS
CUSIP: 23126910
CIK: 1108205
Web: www.curis.com
Phone: (617) 503-6500
Fax: 617-503-6501
Employees: 49
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $37.33
High Stock Price Target: $60.00
Low Stock Price Target: $26.00
Potential Upside/Downside: +156.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,410,000.00
Net Margins: -473.04%
Pretax Margin: -473.04%
Return on Equity: -169.22%
Return on Assets: -54.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.51
Quick Ratio: 4.51

Sales & Book Value

Annual Sales: $10.02 million
Price / Sales: 8.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.34 per share
Price / Book: 4.36

Miscellaneous

Outstanding Shares: 5,890,000
Free Float: 5,610,000
Market Cap: $85.76 million
Optionable: No Data
Beta: 3.72

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. James E. Dentzer (Age 57)
President, CEO, Secretary, Treasurer & Director
Comp: $912.29k
Ms. Diantha Duvall CPA (Age 52)
M.B.A., CFO and Principal Financial & Accounting Officer
Comp: $588.95k
Mr. Mark W. Noel (Age 65)
Vice President of Technology Management & Intellectual Property
Comp: $279.28k
Ms. Elif McDonald
VP of Investor Relations & Corporate Communications
Dr. Reinhard Wilhelm von Roemeling M.D.
Senior Vice President of Clinical Development
Dr. Jonathan B. Zung Ph.D. (Age 59)
Chief Development Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CRIS Stock Analysis - Frequently Asked Questions

Should I buy or sell Curis stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings or view top-rated stocks.
What is Curis' stock price target for 2024?: 3 Wall Street research analysts have issued 1-year price objectives for Curis' shares. Their CRIS share price targets range from $26.00 to $60.00. On average, they predict the company's share price to reach $37.33 in the next year. This suggests a possible upside of 156.4% from the stock's current price.
View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts.
How have CRIS shares performed in 2024?: Curis' stock was trading at $12.75 on January 1st, 2024. Since then, CRIS stock has increased by 14.2% and is now trading at $14.56.
View the best growth stocks for 2024 here.
When is Curis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRIS earnings forecast.
How were Curis' earnings last quarter?: Curis, Inc. (NASDAQ:CRIS) announced its quarterly earnings results on Thursday, February, 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.91) by $0.12. The biotechnology company earned $2.70 million during the quarter, compared to the consensus estimate of $2.95 million. Curis had a negative net margin of 473.04% and a negative trailing twelve-month return on equity of 169.22%. During the same quarter last year, the business earned ($2.40) earnings per share.

When did Curis' stock split?: Curis's stock reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Curis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).
Who are Curis' major shareholders?: Curis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Street Advisors Inc. NC (0.34%).
View institutional ownership trends.
How do I buy shares of Curis?: Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRIS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial